Age-male-albumin-bilirubin-platelet score stratifies hepatocellular carcinoma risk after sustained virological response in hepatitis C-related compensated advanced chronic liver disease

Table 3 Time-dependent diagnostic performance of four noninvasive scoring systems for predicting de novo hepatocellular carcinoma at 1-year, 3-year, 5-year, and 8-year follow-up

Noninvasive scoring system at SVR12	1-year FU AUC (95%CI)	3-year FU AUC (95%CI)	5-year FU AUC (95%CI)	8-year FU AUC (95%CI)
FIB-4	0.64 (0.49-0.78)	0.69 (0.59-0.79)	0.69 (0.60-0.78)	0.69 (0.61-0.78)
APRI	0.61 (0.46-0.75)	0.67 (0.57-0.77)	0.65 (0.56-0.75)	0.66 (0.57-0.75)
ALBI	0.59 (0.44-0.73)	0.67 (0.58-0.76)	0.66 (0.57-0.74)	0.65 (0.56-0.74)
aMAP	0.74 (0.62-0.85)	0.76 (0.68-0.83)	0.74 (0.67-0.82)	0.74 (0.67-0.80)

ALBI: Albumin-bilirubin score; aMAP: Age-male-albumin-bilirubin-platelet score; APRI: Aspartate aminotransferase-to-platelet ratio index; AUC: Area under the curve; CI: Confidence interval; FIB-4: Fibrosis-4 index; FU: Follow-up; SVR12, sustained virological response at 12 weeks after treatment completion.